CELLTRION
Celltrion today announced that the European Commission (EC) has approved the use of SteQeyma® (CT-P43), an ustekinumab biosimilar referencing Stelara®, for the treatment of multiple chronic inflammatory diseases. SteQeyma is approved as a biologic therapy in gastroenterology, dermatology and rheumatology indications.1 Stelara was the first biologic therapy for Crohn’s disease to target interleukin (IL)-12 and IL-23 cytokines, known to play a key role in inflammatory and immune responses.2
The decision from the EC follows a positive opinion recommending SteQeyma from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) in June 2024.3
The EC approval of SteQeyma was based on the totality of evidence, including the results from a Phase III study in adults with moderate to severe plaque psoriasis, in which the primary endpoint was the rate of change in the Psoriasis Area and Severity Index (PASI) for skin symptoms. The clinical results demonstrated that SteQeyma is highly similar to its reference product, Stelara, and has no clinically meaningful differences in terms of efficacy and safety.4,5
“The EC approval of SteQeyma brings an important new therapeutic option to patients and we’re excited to launch this innovative therapy, with a proven track record in Crohn’s and other immune diseases,” said Taehun Ha, Senior Vice President and Head of Europe Division at Celltrion. “This approval, alongside those of Remsima SC and Yuflyma, marks a key milestone in our strategy to strengthen Celltrion’s immunology offering, and with the recent approval of Omlyclo in May, we are looking forward to expanding our portfolio into the dermatology sector. We believe the approval demonstrates our unwavering commitment to expanding patient access to affordable, high-quality biologic medicines.”
SteQeyma is Celltrion’s seventh biosimilar approved for use in the European Union (EU). Alongside Remsima® SC, a subcutaneous formulation of infliximab approved in the EU, SteQeyma joins Celltrion’s distinguished portfolio that includes Remsima® (biosimilar infliximab), Truxima® (biosimilar rituximab), Herzuma® (biosimilar trastuzumab), Yuflyma® (biosimilar adalimumab), Vegzelma® (biosimilar bevacizumab) and Omlyclo® (biosimilar omalizumab).
About SteQeyma® (CT-P43, biosimilar ustekinumab)1
SteQeyma®, formerly known as CT-P43, is a human IL-12 and IL-23 antagonist indicated for multiple immune-mediated diseases. SteQeyma is available in both subcutaneous and intravenous formulations. The subcutaneous injection comes in two strengths: 45mg/0.5 mL or 90mg/1 mL solution in a single-dose, prefilled syringe. The intravenous infusion is provided as a 130mg/26 mL (5mg/mL) solution in a single-dose vial.
About Celltrion
Celltrion is a leading biopharmaceutical company based in Incheon, South Korea that specialises in researching, developing, manufacturing, marketing and sales of innovative therapeutics that improve people's lives worldwide. The company’s solutions include world-class monoclonal antibody biosimilars such as Remsima®, Truxima® and Herzuma®, providing broader patient access globally. Celltrion has also received U.S. FDA and EC approval for Vegzelma®, Yuflyma® and Omlyclo®, FDA approval for Zymfentra®, and EC approval for Remsima® SC. To learn more, please visit www.celltrion.com/en-us.
FORWARD-LOOKING STATEMENT
Certain information set forth in this press release contains statements related to our future business and financial performance and future events or developments involving Celltrion Inc. and its subsidiaries that may constitute forward-looking statements, under pertinent securities laws.
These statements may be identified by words such as “prepares”, “hopes to”, “upcoming”, ”plans to”, “aims to”, “to be launched”, “is preparing, “once gained”, “could”, “with the aim of”, “may”, “once identified”, “will”, “working towards”, “is due”, “become available”, “has potential to”, the negative of these words or such other variations thereon or comparable terminology.
In addition, our representatives may make oral forward-looking statements. Such statements are based on the current expectations and certain assumptions of Celltrion Inc. and its subsidiaries' management, of which many are beyond its control.
Forward-looking statements are provided to allow potential investors the opportunity to understand management’s beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment. These statements are not guarantees of future performance and undue reliance should not be placed on them.
Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or result expressed or implied by such forward-looking statements.
Although forward-looking statements contained in this presentation are based upon what management of Celltrion Inc. and its subsidiaries believes are reasonable assumptions, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Celltrion Inc. and its subsidiaries undertake no obligation to update forward-looking statements if circumstances or management’s estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements.
Trademark
Stelara® is a registered trademark of Johnson & Johnson.
SteQeyma® is a registered trademark of Celltrion, Inc., used under license.
References
1 European Medicines Agency Summary of Product Characteristics (SmPC), SteQeyma.
2 European Medicines Agency. Summary of Product Characteristics (SmPC), STELARA Available at: https://www.ema.europa.eu/en/documents/product-information/stelara-epar-product-information_en.pdf. [Last accessed August 2024].
3 European Medicines Agency. Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 24-27 June 2024. Available at: https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-24-27-june-2024. [Last accessed August 2024].
4 Papp KA et al., Efficacy and Safety of Candidate Biosimilar CT-P43 Versus Originator Ustekinumab in Moderate to Severe Plaque Psoriasis: 28-Week Results of a Randomised, Active-Controlled, Double-Blind, Phase III study. BioDrugs. 2023; Available at: https://link.springer.com/article/10.1007/s40259-023-00630-5. [Last accessed August 2024].
5 Papp K et al., Efficacy and Safety after Switch from Reference Ustekinumab to Ustekinumab Biosimilar (CT-P43) in comparison with the Maintenance Group (CT-P43 or Reference Ustekinumab) in Patients with Moderate-to-Severe Plaque Psoriasis: 1-Year Result. [EADV 2023, Abstract #4035]. Available at: https://eadv.org/wp-content/uploads/scientific-abstracts/EADV-congress-2023/Biologics-immunotherapy-targeted-therapy.pdf. [Last accessed August 2024].
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240819920486/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Tecnotree Included as a Representative Provider in Gartner® Innovation Insight: AI SOC Agents Accelerate CSP SecOps Transformation31.12.2025 11:59:00 CET | Press release
Tecnotree, a global digital platform and services provider for communications service providers (CSPs), today announced that it has been referenced as a Representative Provider alongside Google, Anthropic, Dropzone AI, DRUID, Palo Alto Networks, and Pegasystems in the Gartner® Innovation Insight: “AI SOC Agents Accelerate CSP SecOps Transformation,” published in December 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251231210303/en/ Tecnotree Included as a Representative Provider in Gartner® Innovation Insight: AI SOC Agents Accelerate CSP SecOps Transformation The Gartner Innovation Insight examines the emerging role of AI-driven Security Operations Centre (SOC) agents in CSP environments, outlining how these agents are used to automate and augment security operations across signalling, core networks, RAN, Open RAN, and roaming domains. The research discusses use cases such as alert triage, investigation support, thr
UAE’s Medcare Treats First International SMA Patient With Revolutionary Intrathecal Gene Therapy30.12.2025 15:15:00 CET | Press release
The newly licensed intrathecal gene therapy expands life-changing treatment options for children and adults affected by SMA Medcare Women & Children Hospital has successfully administered a pioneering intrathecal gene therapy for Spinal Muscular Atrophy (SMA) to Hulus, a three-year-old patient from Turkey. This milestone positions Medcare among the first private healthcare providers worldwide to offer this innovative treatment to an older international patient, overcoming previous age and weight limitations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251230695275/en/ World's first international patient, who received intrathecal gene therapy at Medcare Royal Hospital in Dubai, UAE, along with parents, and the hospital team. (Photo: AETOSWire) SMA is a rare neuromuscular disorder that progressively weakens muscles responsible for movement and breathing. This newly licensed one-time therapy addresses the root genetic cause
Amazfit Introduces Active Max: Bigger, Brighter, and Built for Maximum Performance30.12.2025 09:00:00 CET | Press release
The newest member of the Active family blends new design, expanded storage, and longer battery to help users train smarter and reach their goals with confidence. Amazfit, a leading global smart wearable brand by Zepp Health (NYSE: ZEPP), today announces the Amazfit Active Max, the newest member of the Amazfit Active family. Built for everyday athletes and anyone looking to elevate their wellness routine, Active Max blends a 1.5″ ultra-bright AMOLED display, up to 25 days of battery life, easy podcast listening and advanced training tools to support consistent training and clearer visibility across any activity. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251230279762/en/ Bigger Display. Max Clarity: A 1.5″ ultra-bright AMOLED display delivers exceptional clarity in any setting—whether in the gym, outdoors, or on the move. With up to 3,000 nits of peak brightness, the screen ensures real-time stats are always easy to read.
2026 Future of Fitness Report: Experts from Coherent Solutions Turn Years of Fitness Industry Software Engineering Work Into a Guidebook on Future-proof Digital Transformation in Fitness29.12.2025 18:48:00 CET | Press release
Coherent Solutions has released its 2026 Future of Fitness report, capturing years of domain knowledge from helping emerging and global fitness brands drive digital transformation, innovate, and improve member engagement. “The Future of Fitness: Winning with Digital Value Creation” takes lessons from real projects and fitness enthusiasts, turning them into a guidebook for the next era of fitness. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251229965712/en/ New Fitness Tech Whitepaper by Coherent Solutions While the global fitness market is on track to surpass $257 billion, and brands are expanding globally, pioneering new regions, and implementing new technologies, the report highlights the most effective growth trajectory in acknowledging the importance of technology as equal to supporting the fitness community. "Most people only spend 3–5 hours a week in a gym. That leaves 160+ hours where their choices and habits are i
Hanshow and the University of Cambridge Launch Joint Research on Augmented Intelligent Hybrid Wireless Technology25.12.2025 12:34:00 CET | Press release
Hanshow, a global leader in electronic shelf labels (ESL) and digital store solutions, has entered into a multi-year research collaboration with the University of Cambridge, one of the world’s most prestigious academic institutions. The partnership will focus on joint research and innovation in next-generation intelligent hybrid wireless technologies, marking an important milestone in Hanshow’s continued investment in core technologies and long-term innovation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251225988816/en/ This collaboration leverages the University of Cambridge’s deep expertise in fundamental wireless technology research, alongside Hanshow’s extensive industry experience, to further strengthen multi-protocol integration capabilities and expand scalable applications across diverse retail scenarios. Guided by shared principles of innovation, collaboration, openness, and knowledge sharing, the two parties aim
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom